المؤلفون: Liang YH; Graduate Institutes of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.; Center of Genomic and Precision Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Chen KH; Graduate Institutes of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.; Center of Genomic and Precision Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Shao YY; Graduate Institutes of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.

المصدر: Cancer medicine [Cancer Med] 2023 Jul; Vol. 12 (14), pp. 15176-15186. Date of Electronic Publication: 2023 Jun 16.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

مواضيع طبية MeSH: Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/genetics , Colonic Neoplasms*/drug therapy , Antineoplastic Agents*/therapeutic use , Rectal Neoplasms*/drug therapy, Humans ; Bevacizumab/therapeutic use ; Proto-Oncogene Proteins p21(ras)/genetics ; Antibodies, Monoclonal ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cetuximab

المؤلفون: Li YF; Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA. ying_fei.li@novartis.com., Combes FP; Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA., Hoch M; Novartis Institute for Biomedical Research, Basel, Switzerland., Lorenzo S; Novartis Pharmaceutical Corporation, Basel, Switzerland., Sy SKB; Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA., Ho YY; Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA.

المصدر: Clinical pharmacokinetics [Clin Pharmacokinet] 2022 Oct; Vol. 61 (10), pp. 1393-1403. Date of Electronic Publication: 2022 Jun 28.

نوع المنشور: Clinical Trial; Journal Article

بيانات الدورية: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents* , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics, Fusion Proteins, bcr-abl/genetics ; Fusion Proteins, bcr-abl/therapeutic use ; Humans ; Niacinamide/analogs & derivatives ; Philadelphia Chromosome ; Protein Kinase Inhibitors/therapeutic use ; Pyrazoles

المؤلفون: Chen CT; Department of Oncology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan, R.O.C.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C., Hsu CH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, R.O.C., Cheng AL; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, R.O.C.; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan, R.O.C., Shao YY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, R.O.C.; yuyunshao@gmail.com.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan, R.O.C.

المصدر: Anticancer research [Anticancer Res] 2022 Sep; Vol. 42 (9), pp. 4461-4470.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet ISSN: 1791-7530 (Electronic) Linking ISSN: 02507005 NLM ISO Abbreviation: Anticancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Carcinoma, Hepatocellular*/pathology , Chemoembolization, Therapeutic*/methods , Liver Neoplasms*/pathology, Female ; Humans ; Male ; Middle Aged ; Niacinamide/therapeutic use ; Phenylurea Compounds/therapeutic use ; Retrospective Studies ; Sorafenib/therapeutic use ; Treatment Outcome

المؤلفون: Chen SC; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Road, Taiwan, 11217, Taipei, Taiwan., Huang YH; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan., Chen MH; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Road, Taiwan, 11217, Taipei, Taiwan., Hung YP; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Road, Taiwan, 11217, Taipei, Taiwan., Lee RC; Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan., Shao YY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan., Chao Y; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. ychao@vghtpe.gov.tw.; Faculty of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. ychao@vghtpe.gov.tw.; Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Road, Taiwan, 11217, Taipei, Taiwan. ychao@vghtpe.gov.tw.

المصدر: BMC cancer [BMC Cancer] 2022 Jan 11; Vol. 22 (1), pp. 55. Date of Electronic Publication: 2022 Jan 11.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/mortality , Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/drug therapy , Liver Neoplasms*/mortality , Liver Neoplasms*/pathology, Antineoplastic Agents/*therapeutic use , Immune Checkpoint Inhibitors/*therapeutic use , Sorafenib/*therapeutic use, Aged ; Aged, 80 and over ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Propensity Score ; Retrospective Studies

المؤلفون: Shao YY; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei City, Taiwan, yuyunshao@gmail.com.; Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan, yuyunshao@gmail.com., Hsu HW; Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan., Wo RR; Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan., Wang HY; Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan., Cheng AL; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei City, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan.; Department of Internal Medicine, National Taiwan University College of Medicine, Taipei City, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei City, Taiwan., Hsu CH; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei City, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan.

المصدر: Oncology [Oncology] 2022; Vol. 100 (11), pp. 602-611. Date of Electronic Publication: 2022 Sep 14.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Karger Country of Publication: Switzerland NLM ID: 0135054 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0232 (Electronic) Linking ISSN: 00302414 NLM ISO Abbreviation: Oncology Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Hepatocellular*/pathology , Liver Neoplasms*/pathology , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use, Humans ; Mice ; Animals ; Cyclin-Dependent Kinase 9/genetics ; Cyclin-Dependent Kinase 9/metabolism ; Cell Line, Tumor ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Apoptosis/genetics

المؤلفون: Han X; School of Pharmacy, Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, P. R. China., Yu YL; School of Pharmacy, Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, P. R. China., Ma D; School of Pharmacy, Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, P. R. China., Zhang ZY; School of Pharmacy, Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, P. R. China., Liu XH; School of Pharmacy, Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, P. R. China.

المصدر: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2021 Dec; Vol. 36 (1), pp. 344-360.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print Cited Medium: Internet ISSN: 1475-6374 (Electronic) Linking ISSN: 14756366 NLM ISO Abbreviation: J Enzyme Inhib Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*chemical synthesis , Cell Cycle Proteins/*antagonists & inhibitors , Chromones/*chemical synthesis , Enzyme Inhibitors/*chemical synthesis , Nuclear Proteins/*antagonists & inhibitors , Oxadiazoles/*chemistry , Telomerase/*antagonists & inhibitors, Amides/chemical synthesis ; Antineoplastic Agents/metabolism ; Antineoplastic Agents/pharmacology ; Apoptosis/drug effects ; Cell Cycle/drug effects ; Cell Cycle Proteins/chemistry ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Chromones/metabolism ; Chromones/pharmacology ; Drug Design ; Drug Screening Assays, Antitumor ; Enzyme Inhibitors/metabolism ; Enzyme Inhibitors/pharmacology ; Humans ; Inhibitory Concentration 50 ; Nuclear Proteins/chemistry ; Nuclear Proteins/metabolism ; Staurosporine/pharmacology ; Structure-Activity Relationship ; Telomerase/chemistry ; Telomerase/metabolism

المؤلفون: Chen CT; Department of Oncology, National Taiwan University Hospital Hsinchu Branch, Hsinchu 300195, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei 100225, Taiwan., Liu TH; Department of Oncology, National Taiwan University Hospital, Taipei 100225, Taiwan.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 100233, Taiwan., Shao YY; Department of Oncology, National Taiwan University Hospital, Taipei 100225, Taiwan.; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 100233, Taiwan., Liu KL; Department of Medical Imaging, National Taiwan University Hospital, Taipei 100225, Taiwan.; Department of Medical Imaging, National Taiwan University Cancer Center, Taipei 106328, Taiwan., Liang PC; Department of Medical Imaging, National Taiwan University Hospital, Taipei 100225, Taiwan.; Department of Medical Imaging, National Taiwan University Hospital Hsinchu Branch, Hsinchu 300195, Taiwan., Lin ZZ; Department of Oncology, National Taiwan University Hospital, Taipei 100225, Taiwan.; Department of Internal Medicine, College of Medicine, National Taiwan University, Taipei 100233, Taiwan.; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei 106328, Taiwan.

المصدر: International journal of molecular sciences [Int J Mol Sci] 2021 Nov 28; Vol. 22 (23). Date of Electronic Publication: 2021 Nov 28.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

مواضيع طبية MeSH: Hepatic Artery*, Antineoplastic Agents/*administration & dosage , Carcinoma, Hepatocellular/*drug therapy , Liver Neoplasms/*drug therapy, Antineoplastic Combined Chemotherapy Protocols ; Clinical Trials as Topic ; Humans ; Infusions, Intra-Arterial

المؤلفون: Lu Y, Yang S; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Ho YY; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Ji Y; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.

المصدر: Journal of clinical pharmacology [J Clin Pharmacol] 2021 Aug; Vol. 61 (8), pp. 1054-1068. Date of Electronic Publication: 2021 Apr 17.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Aminopyridines/*pharmacokinetics , Antineoplastic Agents/*pharmacokinetics , Neutrophils/*drug effects , Purines/*pharmacokinetics, Adult ; Age Factors ; Aged ; Aminopyridines/pharmacology ; Aminopyridines/therapeutic use ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Area Under Curve ; Body Weight ; Breast Neoplasms/pathology ; Drug Interactions ; Female ; Humans ; Kidney Function Tests ; Liver Function Tests ; Male ; Metabolic Clearance Rate ; Metabolic Networks and Pathways ; Middle Aged ; Models, Biological ; Neoplasm Metastasis ; Purines/pharmacology ; Purines/therapeutic use ; Racial Groups ; Receptor, ErbB-2/metabolism ; Receptors, Progesterone/metabolism ; Sex Factors

المؤلفون: Lin ZZ; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan., Chen BB; Department of Radiology, National Taiwan University Hospital, Taipei, Taiwan., Hung YP; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan., Huang PH; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Shen YC; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Shao YY; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Hsu CH; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Cheng AL; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan., Lee RC; Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan., Chao Y; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.; School of Medicine, National Yang-Ming University, Taipei, Taiwan., Hsu C; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.

المصدر: The oncologist [Oncologist] 2020 Sep; Vol. 25 (9), pp. e1280-e1285. Date of Electronic Publication: 2020 Apr 09.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Carcinoma, Hepatocellular*/drug therapy , Liver Neoplasms*/drug therapy, Axitinib/therapeutic use ; Humans ; Niacinamide/therapeutic use ; Phenylurea Compounds/therapeutic use ; Sorafenib/therapeutic use ; Treatment Outcome

المؤلفون: Lau YY; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. yvonne.lau@novartis.com., Gu W; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Ho YY; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Hong Y; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Zhang X; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Urban P; Novartis Pharma AG, Basel, Switzerland.

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 Sep; Vol. 84 (3), pp. 501-511. Date of Electronic Publication: 2019 Apr 24.

نوع المنشور: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Gene Rearrangement*, Anaplastic Lymphoma Kinase/*genetics , Antineoplastic Agents/*therapeutic use , Brain Neoplasms/*drug therapy , Carcinoma, Non-Small-Cell Lung/*drug therapy , Lung Neoplasms/*drug therapy , Pyrimidines/*therapeutic use , Sulfones/*therapeutic use, Adult ; Aged ; Aged, 80 and over ; Brain Neoplasms/genetics ; Brain Neoplasms/secondary ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prognosis ; Survival Rate ; Time Factors ; Young Adult